ONCY Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-0.086

-14%

-0.073

-8.13%

-0.074

+6.43%

Estimates Revision

The market is revising No Change the revenue expectations for Oncolytics Biotech Inc. (ONCY) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -19.36%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+18.46%

In Past 3 Month

Stock Price

Go Down

-19.36%

In Past 3 Month

6 Analyst Rating

Wall Street analysts forecast ONCY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ONCY is 5.50 USD with a low forecast of 3.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

1 Hold

0 Sell

Strong Buy

Current: 0.000

Low

3.00

Averages

5.50

High

10.00

Current: 0.000

Low

3.00

Averages

5.50

High

10.00

H.C. Wainwright

upgrade

$5 -> $10

2025-11-17

Reason

H.C. Wainwright

Price Target

$5 -> $10

2025-11-17

upgrade

Reason

H.C. Wainwright raised the firm's price target on Oncolytics to $10 from $5 and keeps a Buy rating on the shares. The firm says the company's "compelling" data in gastrointestinal tumors increase its confidence ahead of the FDA meeting. H.C. Wainwright is increasingly confident that pelareorep is advancing toward "actionable regulatory pathways" across three "high-value" cancer indications.

Lake Street

Chad Messer

initiated

2025-08-13

Reason

Lake Street

Chad Messer

Price Target

2025-08-13

initiated

Reason

Lake Street analyst Chad Messer initiated coverage of Oncolytics with a Buy rating and $7 price target. Oncolytics is emerging under new management with a clear pivotal strategy focused in frontline metastatic pancreatic ductal adenocarcinoma, where \"existing clinical data is strong and the unmet need is clear,\" the analyst tells investors. Pelareorep has shown \"impressive\" increases in survival compared to both historical results and in a randomized study when added to standard of care regimens, added the analyst, who also notes that the FDA has granted fast track designation to pelareorep in pancreatic cancer.

JonesResearch

Soumit Roy

Buy

Hold

downgrade

2025-05-16

Reason

JonesResearch

Soumit Roy

Price Target

2025-05-16

downgrade

Buy

Hold

Reason

JonesResearch analyst Soumit Roy downgraded Oncolytics to Hold from Buy without a price target. The company is continuing to actively search for a Chief Executive Officer, as well as exploring potential business development opportunities, the analyst tells investors in a research note. The firm says it needs to get a better understanding on Oncolytics' path forward "as there is an immediate need for capital."

RBC Capital

Douglas Miehm

Buy

Maintains

$6 → $5

2025-03-10

Reason

RBC Capital

Douglas Miehm

Price Target

$6 → $5

2025-03-10

Maintains

Buy

Reason

RBC Capital lowered the firm's price target on Oncolytics to C$5 from C$6 and keeps an Outperform rating on the shares.

HC Wainwright & Co.

Patrick Trucchio

Strong Buy

Reiterates

2025-03-10

Reason

HC Wainwright & Co.

Patrick Trucchio

Price Target

2025-03-10

Reiterates

Strong Buy

Reason

Maxim Group

Jason McCarthy

Strong Buy

Maintains

$5 → $3

2025-03-10

Reason

Maxim Group

Jason McCarthy

Price Target

$5 → $3

2025-03-10

Maintains

Strong Buy

Reason

Maxim lowered the firm's price target on Oncolytics to $3 from $5 and keeps a Buy rating on the shares. The firm is adjusting its model to reflect the expected dilution from the company needing to raise capital in the near-term to fund its cancer programs, the analyst tells investors in a research note. Maxim adds however that it remains positive on the opportunities for Oncolytics in pela in breast and pancreatic cancer.

Valuation Metrics

The current forward P/E ratio for Oncolytics Biotech Inc (ONCY.O) is -4.38, compared to its 5-year average forward P/E of -4.69. For a more detailed relative valuation and DCF analysis to assess Oncolytics Biotech Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-4.69

Current PE

-4.38

Overvalued PE

-2.83

Undervalued PE

-6.55

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-2.70

Current EV/EBITDA

-2.79

Overvalued EV/EBITDA

-1.19

Undervalued EV/EBITDA

-4.21

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

21.72

Current PS

0.00

Overvalued PS

62.71

Undervalued PS

-19.27

Financials

Annual

Quarterly

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

ONCY News & Events

Events Timeline

No data

News

4.5

01-09Globenewswire

Oncolytics Proposes Jurisdiction Change to Nevada to Simplify Structure

3.5

01-08Globenewswire

Oncolytics Biotech Fortifies IP Protection, Extends Pelareorep Commercial Runway to 2044

4.5

01-07Globenewswire

GoldHaven Resources Reports Bonanza Grade Assays from Magno Project

People Also Watch

Frequently Asked Questions

What is Oncolytics Biotech Inc (ONCY) stock price today?

The current price of ONCY is 0.9677 USD — it has decreased -2.42 % in the last trading day.

What is Oncolytics Biotech Inc (ONCY)'s business?

Oncolytics Biotech Inc. is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype, turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. The Company is also advancing its programs in hormone receptor-positive / human epidermal growth factor 2-negative (HR+/ HER2-) advanced and metastatic breast cancer (mBC) and metastatic pancreatic ductal adenocarcinoma (PDAC) to registration-enabled clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

What is the price predicton of ONCY Stock?

What is Oncolytics Biotech Inc (ONCY)'s revenue for the last quarter?

Oncolytics Biotech Inc revenue for the last quarter amounts to -13.84M USD, increased 39.81 % YoY.

What is Oncolytics Biotech Inc (ONCY)'s earnings per share (EPS) for the last quarter?

Oncolytics Biotech Inc. EPS for the last quarter amounts to -6658000.00 USD, increased 36.88 % YoY.

What changes have occurred in the market's expectations for Oncolytics Biotech Inc (ONCY)'s fundamentals?

How many employees does Oncolytics Biotech Inc (ONCY). have?

Oncolytics Biotech Inc (ONCY) has 27 emplpoyees as of January 10 2026.

What is Oncolytics Biotech Inc (ONCY) market cap?

Today ONCY has the market capitalization of 104.13M USD.